Indication
Non-Alcoholic Steatohepatitis
15 clinical trials
20 products
1 drug
Product
Saroglitazar MagnesiumClinical trial
A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 2 mg and 4 mg in Patients With Non-alcoholic SteatohepatitisStatus: Completed, Estimated PCD: 2020-07-02
Product
SaroglitazarProduct
PlacebosProduct
HSK31679Clinical trial
A Multicenter, Double-blind, Placebo Randomized , Phase2b Study to Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH).Status: Recruiting, Estimated PCD: 2026-01-01
Product
PlaceboClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered HEC96719 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic SteatohepatitisStatus: Completed, Estimated PCD: 2023-09-05
Product
HEC96719Clinical trial
An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential of Oral Insulin to Reduce Liver Fat Content and Fibrosis in Patients With Nonalcolholic Steatohepatitis (NASH)Status: Completed, Estimated PCD: 2020-03-01
Product
InsulinProduct
Oral InsulinProduct
EDP-305Clinical trial
A Phase 2b Randomized, Double-Blind, Placebo-controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects With Liver Biopsy Proven Non-alcoholic Steatohepatitis (NASH) (ARGON-2)Status: Terminated, Estimated PCD: 2021-10-04
Product
PemvidutideClinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 Once Daily on Steatohepatitis in Patients With Non-Alcoholic Steatohepatitis (NASH).Status: Completed, Estimated PCD: 2015-02-01
Product
GFT505Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-range, Proof-of-concept, 24-week Treatment Study of IVA337 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)Status: Completed, Estimated PCD: 2020-02-20
Product
IVA337Clinical trial
Comparative Study Evaluating the Outcome of Febuxostat Versus Vitamin E in Hyperuricemia Patients With Non-alcoholic Steatohepatitis Without CirrhosisStatus: Recruiting, Estimated PCD: 2024-05-30
Product
Vitamin EProduct
FebuxostatClinical trial
A Pilot Study to Treat Adults With Non-Alcoholic Steatohepatitis With Oral IdebenoneStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Product
IdebenoneDrug
VarlilumabClinical trial
Clinical Study Evaluating the Efficacy and Safety of Diosmin on Non-diabetic Patients With Non-alcoholic Steatohepatitis.Status: Recruiting, Estimated PCD: 2023-10-10
Product
DiosminClinical trial
The Effect of Vitamin E and Docosahexaenoic Acid Ethyl Ester on Non-Alcoholic Fatty Liver Disease (NAFLD) - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)Status: Completed, Estimated PCD: 2022-09-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALG-055009 in Non-Cirrhotic Adults With Metabolic Dysfunction-Associated SteatohepatitisStatus: Active (not recruiting), Estimated PCD: 2024-11-25
Product
ALG-055009Clinical trial
Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic SteatohepatitisStatus: Recruiting, Estimated PCD: 2025-02-20
Product
LFMT-capsulesClinical trial
Non-Alcoholic Fatty Liver Disease, the Hepatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)Status: Recruiting, Estimated PCD: 2024-08-01
Product
Semaglutide